Please enter verification code
Confirm
Expression of mRNA (Bcl-2, p53, Caspase 9, Caspase 3 and NGX 6) on Ovarium Carcinoma
American Journal of Clinical and Experimental Medicine
Volume 8, Issue 6, November 2020, Pages: 110-116
Received: Nov. 26, 2020; Accepted: Dec. 11, 2020; Published: Dec. 22, 2020
Views 50      Downloads 15
Authors
Ardhanu Kusumanto, Department of Obstetric & Gynecology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia
Heru Prajadmo, Department of Obstetric & Gynecology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia
Indwiyani Astuti, Department of Pharmacology & Biomolecular, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia
Didik Setyo Herianto, Department of Clinical Pathology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia
Article Tools
Follow on us
Abstract
Ovarian Cancer (OC) is a global health crisis and one of the deadly gynecological cancers among women worldwide. According to 2008-2012 U.S. cancer statistics, 12.7 per 100,000 women were newly diagnosed with ovarian cancer. During that same time period, the death rate was 7.7 per 100,000 women (Garcia et all, 2007, Wasana Sumanasekera et al 2018). Despite advances in medical and surgical treatment, attempts at early diagnosis, and a clearer picture of the etiology of this disease, increases in long-term survival have been small (Michael G et al, 1995). Because ovarian cancer is usually found at an advanced stage, the survival rate is lower than for other types of cancer (such as breast cancer) that are easier to detect at an early stage. If ovarian cancer is found early and treated, survival rates improve to more than 90%. (Janet M et al. 2011). Data from various immuno-hystochemical researchs, in epithelial ovarian carcinoma (EOC) showed that protein expresion is able to predict the level of progessivity and respond of chemotherapy. The aim of the study is to evaluate the relationship between protein expresion of Bcl-2 mRNA, p53 mRNA, Caspase-9 mRNA, Caspase-3 mRNA and NGX6 mRNA in various prognostic factors and respond of cysplatin based chemotherapy for ephithel ovarian cancer (EOC). Result showed there were positive relationship between Bcl-2 mRNA and P53 mRNA with the hystological type, Grade and clinical stage of EOC, however there was a negative relationship with Caspase-9 mRNA, Caspase-3 mRNA dan NGX6 mRNA, especially for Caspase-9 mRNA showed signicantly lower (p=0.024). The study demonstrated a negative relationship between NGX6 mRNA, BCl-2 mRNA and P53 mRNA expresion with the respond of Chemotherapy to EOC, however there was a positive relationship between Casp9 mRNA and Casp3 mRNA. Summeries Various level and grade of Ovarian carcinoma have positive relationship with the expresion of Bcl-2 mRNA, p53 mRNA, and negative relationship with Caspase-9 mRNA, Caspase-3 mRNA and NGX6 mRNA. The study demonstrated a negative relationship between NGX6 mRNA, Bcl-2 mRNA and P53 mRNA expresion with the respond of Chemotherapy to EOC, however there was a positive relationship between Casp9 mRNA and Casp3 mRNA.
Keywords
Ovarian Carcinoma, Expresion of Bcl-2 Mrna, p53 Mrna, Caspase-9 Mrna, Caspase-3 Mrna and Ngx6 Mrna, Respond Chemotherapy
To cite this article
Ardhanu Kusumanto, Heru Prajadmo, Indwiyani Astuti, Didik Setyo Herianto, Expression of mRNA (Bcl-2, p53, Caspase 9, Caspase 3 and NGX 6) on Ovarium Carcinoma, American Journal of Clinical and Experimental Medicine. Vol. 8, No. 6, 2020, pp. 110-116. doi: 10.11648/j.ajcem.20200806.12
Copyright
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
ClaraIngaramo M, Sánchez JA, Dekanty A: Regulation and function of p53: A perspective from Drosophila studies Elsevier, Mechanisms of Development, (154): 82-90, December 2018.
[2]
Coleman, M. P., Forman, D., Bryant, H., Butler, J., Rachet, B., Maringe, C., Nur, U., Tracey, E., Coory, M., Hatcher, J., McGahan, C. E., Turner, D., Marrett, L., Gjerstorff, M. L., Johannesen, T. B., Adolfsson, J., Lambe, M., Lawrence, G., Meechan, D., … Richards, M. A. (2011). Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the international cancer benchmarking partnership): An analysis of population-based cancer registry data. The Lancet, 377 (9760), 127–138. https://doi.org/10.1016/S0140-6736(10)62231-3.
[3]
Deng, F., Xu, X., Lv, M., Ren, B., Wang, Y., Guo, W., Feng, J., & Chen, X. (2017). Age is associated with prognosis in serous ovarian carcinoma. J. f Ovarian Research, 10 (1), 1–9. https://doi.org/10.1186/s13048-017-0331-6.
[4]
Fauvet, R., Dufournet, C., Poncelet, C., Uzan, C., Hugol, D., & Daraï, E. (2005). Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours. J. Surg Oncol, 92 (4), 337–343. https://doi.org/10.1002/jso.20424.
[5]
Ghosh, A., Stewart, D., & Matlashewski, G. (2004). Regulation of Human p53 Activity and Cell Localization by Alternative Splicing. Mol. Cell. Biol, 24 (18), 7987–7997. https://doi.org/10.1128/mcb.24.18.7987-7997.2004.
[6]
Isobe, M., Emanuel, B. S., Givol, D., Oren, M., & Croce, C. M. (1986). Localization of gene for human p53 tumour antigen to band 17p13. Nature, 320 (6057), 84–85. https://doi.org/10.1038/320084a0.
[7]
Kern, S. E. (1994). p53: Tumor suppression through control of the cell cycle. Gastroenterology, 106 (6), 1708–1711. https://doi.org/10.1016/0016-5085(94)90431-6.
[8]
Kerr, J., Wyllie, A., & Currie, A. (2005). Apoptosis: A basic biological phenomenon with wide-ranging implications in human disease. J. Internal Med., 258 (6), 479–517. https://doi.org/10.1111/j.1365-2796.2005.01570.x.
[9]
Kim, D. J., Lee, M. H., Park, T. I., & Bae, H. I. (2006). Expression and mutational analysis of c-kit in ovarian surface epithelial tumors. Journal of Korean Medical Science, 21 (1), 81–85. https://doi.org/10.3346/jkms.2006.21.1.81.
[10]
Lheureux S, Braunstein M, Oza AM: Epithelial Ovarian Cancer: Evolution of Management in the Era of Precision Medicine, CA Cancer J Clin 2019; 69: 280-304.
[11]
Lindsey A. Torre, Britton Trabert, Carol E. DeSantis, Kimberly D. Miller, Goli Samimi, Carolyn D. Runowicz, Mia M. Gaudet, Ahmedin Jemal, and Rebecca L. Siegel: Ovarian Cancer Statistics, 2018 CA Cancer J Clin. 2018 Jul; 68 (4): 284–296.
[12]
McGuire, W. P. (2009). Maintenance therapy for ovarian cancer: Of Helsinki and Hippocrates. Journal of Clinical Oncology, 27 (28), 4633–4634. https://doi.org/10.1200/JCO.2009.23.6653.
[13]
McIlwain, D. R., Berger, T., & Mak, T. W. (2013). Caspase functions in cell death and disease. Cold Spring Harbor Perspectives in Biology, 5 (4), 1–28. https://doi.org/10.1101/cshperspect.a008656.
[14]
Momenimovahed Z, Tiznobaik A, Taheri S and Salehiniya H: Ovarian cancer in the world: epidemiology and risk factors, Int J Womens Health. 2019; 11: 287–299. Published online 2019 Apr 30. doi: 10.2147/IJWH.S197604.
[15]
Omura, G., Blessing, J. A., Ehrlich, C. E., Miller, A., Yordan, E., Creasman, W. T., & Homesley, H. D. (1986). A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group study. Cancer, 57 (9), 1725–1730. https://doi.org/10.1002/1097-0142(19860501)57:9<1725::AID-CNCR2820570903>3.0.CO;2-J.
[16]
Palmen E, Ebisch I, Dolstra H, Mattias Hällbrink, Leon F A G Massuger, Roland Brock Dirk van den Brand Mark A J Gorris, Alexander H van Asbeck, et al: Peptide-mediated delivery of therapeutic mRNA in ovarian cancer. Eur J Pharm Biopharm. 2019 Aug; 141: 180-190. doi: 10.1016/j.ejpb.2019.05.014. Epub 2019 May 16.
[17]
Razak Amanullah NA, Poothiode U, Vilasiniamma L: Expression of P53 in epithelial ovarian tumors: Indian J, Patol, Microbiol 2020; 63: 235-40.
[18]
Reid, B. M., Permuth, J. B., & Sellers, T. A. (2017). Epidemiology of ovarian cancer: a review. Cancer Biology and Medicine, 14 (1), 9–32. https://doi.org/10.20892/j.issn.2095-3941.2016.0084.
[19]
Schuyer, M., Van der Burg, M. E. L., Henzen-Logmans, S. C., Fieret, J. H., Klijn, J. G. M., Look, M. P., Foekens, J. A., Stoter, G., & Berns, E. M. J. J. (2001). Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: A multifactorial analysis of TP53, p21, BAX and BCL-2. British Journal of Cancer, 85 (9), 1359–1367. https://doi.org/10.1054/bjoc.2001.2101.
[20]
Skirnisdóttir, I., Sorbe, B., & Seidal, T. (2001). P53, bcl-2, and bax: Their relationship and effect on prognosis in early stage epithelial ovarian carcinoma. International Journal of Gynecological Cancer, 11 (2), 147–158. https://doi.org/10.1046/j.1525-1438.2001.01003.x.
[21]
Solomon, E., Martin, C., Martin, D. W., & Berg, L. R. (2008). Biology (8th ed.). Thomson Brooks/Cole.
[22]
Tavassoli, F., & Devilee, P. (2003). Pathology and Genetics: Tumours of the Breast and Female Genital Organs. IARC Press.
[23]
Wang YT, Sun XY, Wang H, Huang TT, Wang Y, Yang MX,: Effects of NGX6 expression on proliferation and invasion of nasopharyngeal carcinoma cells and survival of patients, Eur Rev Med Pharmacol Sci. 2017 Dec; 21 (23): 5378-5385. doi: 10.26355/eurrev_201712_13923.
[24]
Xiao, J., Zhou, Y., & Zhu, W. (2015). Association of ultrasonographic features with NGX6 expression and prognosis in invasive ductal breast carcinoma. International Journal of Clinical and Experimental Pathology, 8 (6), 6458–6465.
[25]
Xu, X., Deng, F., Lv, M., Ren, B., Guo, W., & Chen, X. (2016). Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer. Journal of Ovarian Research, 9 (1), 1–8. https://doi.org/10.1186/s13048-016-0294-z.
[26]
Zhao, W. J., & Wang, K. (2013). NGX6 expression improves the sensitivity of tamoxifen-resistant MCF-7 cells through modulation of the Smad signaling pathway. International Journal of Oncology, 42 (6), 2060–2068. https://doi.org/10.3892/ijo.2013.1886.
[27]
Ardhanu Kusumanto.(2020). Platinum based chemotherapy for Ovarian carcinoma, Bali med. J, (9) 1: 404-407. P-ISSN. 2089-1180, E-ISSN. 2302-2914.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186